title: [Early phase II trial of oral etoposide administered for 21 consecutive days in patients with cervical or ovarian cancer. ETP 21 Study Group--Cervical-Ovarian Cancer Group].
abstract: We conducted multi-site early phase II trial or oral etoposide administered for 21 consecutive days in patients with cervical or ovarian cancer in cooperation with 19 institutes. Fifty mg/body of oral etoposide was administered daily for 21 consecutive days. Cycles were repeated every 28 days. In cervical cancer, 24 patients were enrolled and 17 of them were evaluated. The overall response rate including CR and PR was 23.5% (4/17). In ovarian cancer, 18 patients out of 21 enrolled were evaluated. The overall response rate was 16.7% (3/18). The primary toxicity observed was myelosuppression such as leukopenia, neutropenia, hemoglobin decrease and thrombocytopenia. Other adverse effects were anorexia, nausea, vomitting, fatigue, alopecia and stomatitis. From these results we concluded that oral etoposide administered for 21 consecutive days was effective against cervical cancer.
authors.affiliation: Dept. of Obstetrics and Gynecology, Kinki University School of Medicine.
authors.forename: K
authors.initials: K
authors.lastname: Noda
authors.forename: K
authors.initials: K
authors.lastname: Tanaka
authors.forename: M
authors.initials: M
authors.lastname: Ozaki
authors.forename: K
authors.initials: K
authors.lastname: Hirabayasi
authors.forename: K
authors.initials: K
authors.lastname: Hasegawa
authors.forename: I
authors.initials: I
authors.lastname: Nishiya
authors.forename: M
authors.initials: M
authors.lastname: Yakushiji
authors.forename: R
authors.initials: R
authors.lastname: Izumi
authors.forename: Y
authors.initials: Y
authors.lastname: Tomoda
authors.forename: Y
authors.initials: Y
authors.lastname: Ogita
authors.forename: H
authors.initials: H
authors.lastname: Sugimori
authors.forename: T
authors.initials: T
authors.lastname: Yamabe
authors.forename: R
authors.initials: R
authors.lastname: Kudo
authors.forename: A
authors.initials: A
authors.lastname: Yajima
authors.forename: Y
authors.initials: Y
authors.lastname: Terashima
authors.forename: S
authors.initials: S
authors.lastname: Fujii
authors.forename: Y
authors.initials: Y
authors.lastname: Suzuoki
authors.forename: H
authors.initials: H
authors.lastname: Okada
authors.forename: I
authors.initials: I
authors.lastname: Kono
authors.forename: K
authors.initials: K
authors.lastname: Ochiai
authors.forename: T
authors.initials: T
authors.lastname: Yamamoto
authors.forename: M
authors.initials: M
authors.lastname: Ikeda
authors.forename: N
authors.initials: N
authors.lastname: Umesaki
authors.forename: T
authors.initials: T
authors.lastname: Saito
authors.forename: H
authors.initials: H
authors.lastname: Niitani
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D000855:Anorexia / Q000139:chemically induced; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009503:Neutropenia / Q000139:chemically induced; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D013921:Thrombocytopenia / Q000139:chemically induced; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D005047:Etoposide